Trial Profile
Open, single-arm phase II study assessing efficacy of Zarnestra [tipifarnib] combined with tamoxifen in patients with advanced or metastatic breast cancer expressing the estrogen and/or progesterone receptor
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary) ; Tamoxifen
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 30 Oct 2005 New trial record.